5 Key Takeaways

• 1

  GLP-1 receptor agonists may lower the risk of primary open-angle glaucoma compared to metformin in diabetes patients.

• 2

  These medications exhibit neuroprotective and anti-inflammatory properties that could benefit glaucoma management.

• 3

  GLP-1 receptor agonists may stabilize vascular autoregulation and modulate neuroinflammatory pathways early in glaucoma.

• 4

  The connection between metabolic health and optic nerve health suggests a need for optometrists to consider systemic medications.

• 5

  The emerging metabolic-glaucoma connection represents a significant area for future research and clinical attention.